Meeting
2022 ASCO Annual Meeting
Association between lung immune prognostic index, microbiome, and immunotherapy outcomes in non–small cell lung cancer.
Authors
Edouard Auclin
CRCHUM, Montreal, QC, Canada
Edouard Auclin , Alexis Nolin-Lapalme , Corentin Richard , Julie Malo , Marion Tonneau , Myriam Benlaifaoui , Mayra Ponce , Meriem Messaoudene , Yusuke Okuma , Taiki Hakozaki , Bertrand Routy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9050)
DOI
10.1200/JCO.2022.40.16_suppl.9050
Abstract #
9050
Poster Bd #
38
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki
Poster
2023 ASCO Annual Meeting
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
First Author: Lova Sun
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau
Poster
2020 ASCO Virtual Scientific Program
Physiologic colonic uptake of 18F-FDG on PET/CT predicts immunotherapy response and gut microbiome diversity in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Lena Cvetkovic